Molling Johan W, Moreno Maria, van der Vliet Hans J J, von Blomberg B Mary E, van den Eertwegh Alfons J M, Scheper Rik J, Bontkes Hetty J
VUMC Institute for Cancer and Immunology (V-ICI), Division of Immune Therapy, Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
J Immunol Methods. 2007 Apr 30;322(1-2):70-81. doi: 10.1016/j.jim.2007.02.002. Epub 2007 Feb 23.
Invariant Natural Killer T (iNKT) cells are CD1d restricted innate lymphoid cells with an invariant T cell receptor (TCR) alpha chain gene rearrangement (Valpha24-Jalpha18 in human and Valpha14-Jalpha18 in mouse). iNKT cells play a pivotal role in anti-tumor immune responses via cytokine mediated transactivation of various cells which mediate innate and adaptive immune responses. Here we describe, to our knowledge for the first time, the generation of long-term mouse spleen derived iNKT cell lines. We found that dendritic cells (DC) derived from the D1 line, but not Mf4/4 macrophages, loaded with the artificial iNKT cell ligand alpha-Galactosylceramide (alphaGalCer) could be employed to expand iNKT cells in vitro. Furthermore, exogenously added IL-7, but not IL-2 or IL-15 had a pronounced additive effect on iNKT cell expansion. Using this method up to 10(8) iNKT cells could be obtained from one spleen within 12 to 14 weeks, and cell lines could be continued for up to 24 months. Importantly, the iNKT cell lines had retained the capacity to swiftly secrete substantial amounts of both T helper (Th) 1 and Th2 cytokines upon activation. In conclusion we have generated iNKT cell lines with high yields that can be maintained for up to 24 months, by repeated stimulation using alpha-GalCer loaded D1.DC and IL-7. These in vitro expanded iNKT cells preserved the capacity to swiftly produce both Th1 and Th2 type cytokines and are currently being utilized in pre-clinical adoptive transfer models to identify and optimize the characteristics of therapeutically effective iNKT cells in an anti-tumor setting.
不变自然杀伤T(iNKT)细胞是受CD1d限制的固有淋巴细胞,具有不变的T细胞受体(TCR)α链基因重排(人类为Vα24-Jα18,小鼠为Vα14-Jα18)。iNKT细胞通过细胞因子介导的各种细胞的反式激活在抗肿瘤免疫反应中发挥关键作用,这些细胞介导固有免疫和适应性免疫反应。在此,据我们所知,我们首次描述了长期小鼠脾脏来源的iNKT细胞系的产生。我们发现,负载人工iNKT细胞配体α-半乳糖神经酰胺(αGalCer)的D1系树突状细胞(DC),而非Mf4/4巨噬细胞,可用于体外扩增iNKT细胞。此外,外源性添加的IL-7,而非IL-2或IL-15,对iNKT细胞扩增具有显著的累加效应。使用这种方法,在12至14周内可从一个脾脏获得多达10^8个iNKT细胞,并且细胞系可持续长达24个月。重要的是,iNKT细胞系在激活后保留了迅速分泌大量辅助性T(Th)1和Th2细胞因子的能力。总之,我们通过使用负载αGalCer的D1.DC和IL-7进行反复刺激,产生了高产率的iNKT细胞系,该细胞系可维持长达24个月。这些体外扩增的iNKT细胞保留了迅速产生Th1和Th2型细胞因子的能力,目前正用于临床前过继性转移模型,以识别和优化抗肿瘤环境中治疗有效的iNKT细胞的特性。